Comments on spironolactone

   Spironolactone is a steroid-like molecule which is competitive inhibitor of aldosterone and other mineralocorticoids. It acts in the distal renal tubule to interfere with aldosterone mediated effects on sodium and potassium. However, spironolactone is not a particularly effective diuretic. It inhibits reabsorption of less than 2% of filtered sodium. It is most effective in clinical conditions associated with high circulating levels of aldosterone such as is seen in with nephrotic syndrome, congestive heart failure, and hepatic diseases with ascites (Wahlig. Pediatr Clin N A 1992; 19:251). The major use of this diuretic is to prevent urinary losses of potassium induced by other diuretics (Chemtob, Pediatr Clin N A 1989; 36:1231-50). Spironolactone is contraindicated in the presence of anuria or hyperkalemia. The monitoring of serum potassium levels is critical when treating an infant with spironolactone. As such, it does not produce a large diuresis (at this point most of the sodium has already been reabsorbed). When other diuretics are used though, larger amounts of sodium can be delivered to the distal tubule. See diuretic  for comparisons of the effects and complications of the different diuretics. Once started, the effect of the drug may not be seen for 2 to 3 days since it depends upon the synthesis of a peptide which interacts with aldosterone. Once the drug is stopped, there is also a delay of several days before the drug's activity diminishes because of the persistence of these peptides. The half-life reported for healthy adults varies from 10 to 25 hours, however there are no pharmacokinetic studies in infants. Scattered reports have shown that spironolactone improves diuresis in children with liver disease, infants with congestive heart failure secondary to congenital heart disease, or in infants with cor pulmonale secondary to BPD. One would expect that the effects would be increased with significant liver or renal disease (Roberts. Drug Therapy in Infants. Philadelphia: W. B. Saunders, 1984:243-44).

      

Return to Spironolactone,   Home Page, A to C, D to H, I to M, N to Q, R to U, or V to Z.